JSC BAST (KASE:BAST)

Verve Therapeutics Cash Flow Statement

Financials in millions KZT. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-2,421	-2,731	-4,239	-494.72	-1,201	-2,680
Depreciation & Amortization	886.38	829.78	668.27	496.35	293.16	273.53
Other Amortization	9.07	8.38	7.03	0.28	0.37	0.58
Other Operating Activities	-1,214	-2,145	1,612	766.05	549.86	1,343
Operating Cash Flow	-2,739	-4,038	-1,952	767.97	-357.32	-1,063
Capital Expenditures	33.99	-29.77	-460.6	-2,279	-4,729	-816.31
Investment in Securities	-	-	-	-	-239.73	-
Other Investing Activities	205.31	-464.81	0.06	1.54	1.82	414.64
Investing Cash Flow	239.3	-494.58	-460.54	-2,278	-4,967	-401.67
Long-Term Debt Issued	-	4,700	2,631	393.73	2,232	3,688
Long-Term Debt Repaid	-	-101.36	-2,345	-194.62	-4,689	-5,606
Net Debt Issued (Repaid)	2,491	4,599	286.84	199.11	-2,457	-1,917
Issuance of Common Stock	-	-	2,219	1,200	7,853	3,387
Other Financing Activities	12.56	12.56	-	-	-	-
Financing Cash Flow	2,503	4,611	2,506	1,399	5,396	1,469
Foreign Exchange Rate Adjustments	-0.71	-0.11	-0.7	39.74	0.83	-1.63
Net Cash Flow	2.62	78.46	92.38	-71.01	72.11	3.26
Free Cash Flow	-2,705	-4,068	-2,413	-1,511	-5,087	-1,879
Free Cash Flow Margin	-	-1955.63%	-100.66%	-24.15%	-193.35%	-99.55%
Free Cash Flow Per Share	-1439.97	-2165.34	-1314.40	-1015.34	-5469.47	-4961.90
Cash Interest Paid	-	-	-	115.16	3.15	256.66
Cash Income Tax Paid	9.65	9.67	-	-	0.03	0.02
Levered Free Cash Flow	-1,752	-3,275	-1,061	-1,527	-5,522	-1,983
Unlevered Free Cash Flow	-1,475	-3,031	-997.87	-1,325	-5,130	-1,385
Change in Net Working Capital	1,394	2,657	-1,129	-595.11	365.17	73.86

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.